HSF1 and Parkinsonism: Furthermore, Ekimova et al. [55] demonstrated that the pharmacological activation of HSF1 with the echinochrome-derived compound U-133 increased HSP70 levels, prevented α-synuclein aggregation, microglial activation, and neuronal loss in the substantia nigra, while also reversing motor impairments characteristic of the Parkinson’s model.